Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.625 USD | -13.62% | -10.87% | -24.11% |
04:29pm | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
04/06 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.11% | 52Cr | |
+54.05% | 5.57TCr | |
+41.08% | 3.99TCr | |
-5.75% | 3.96TCr | |
-5.56% | 2.82TCr | |
+16.35% | 2.63TCr | |
-20.14% | 1.89TCr | |
+32.64% | 1.22TCr | |
+26.96% | 1.21TCr | |
+2.23% | 1.21TCr |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Transcript : COMPASS Pathways plc - Shareholder/Analyst Call